Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

References 19

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.
    Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples · 1977

    No notice
11. 11.
    Assessment of response to therapy in advanced breast cancer · 1977

    No notice
12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 10

• Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) · 2022
  No notice
• Japanese gastric cancer treatment guidelines 2018 (5th edition) · 2020
  No notice
• Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer · 2019
  No notice
• Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer · 2017
  Corrected
• Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer · 2006
  No notice
• Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF · 2005
  No notice
• A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients · 2005
  No notice
• Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer · 2003
  No notice
• Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial · 2002
  No notice
• Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial · 1999
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.